Veracyte, Inc.
NASDAQ:VCYTBiotechnology
+$1.83 today
- Market cap
- $2.06B
- Beta
- 1.98
- P/E (TTM)
- 48.0
- EPS (TTM)
- $1.11
Volume 2.45M
Average 1.05M
VCYT Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Veracyte, Inc.NASDAQ: VCYT
Revenue · Q2 FY2026 · quarter ended Jun 2026
Revenue grows in line with its trailing trend
Q2 FY2026 revenue of $150.32M rose 15.5% year over year, behind the +17.3% change in trailing-twelve-month revenue. Sequentially, it rose 8.1% from the prior quarter. Over 3 fiscal years it compounded at +20.4% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 7 analysts of $591.01M (+14.3%) for the fiscal year ending Dec 2026, a slowdown from the +16.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $150.32M+8.1% QoQ
- Last fiscal yearDec 2025
- $517.15M+16.0% YoY
- LTMJun 2026
- $561.9M+17.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +15.5% | +11.6% | -3.9 pp |
| 1 year | +16.0% | +14.3% | -1.7 pp |
| 3-year CAGR | +20.4% | +10.2% | -10.2 pp |
| 5-year CAGR | +12.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 517.15M USD
- Year-over-year change
- +16.0%
- 4-year CAGR
- +23.9%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 517.15M | +16.0% |
| FY2024 | 2024-12-31 | 445.76M | +23.5% |
| FY2023 | 2023-12-31 | 361.05M | +21.8% |
| FY2022 | 2022-12-31 | 296.54M | +35.1% |
| FY2021 | 2021-12-31 | 219.51M | — |
Revenue vs competitors
How VCYT compares with its peers on the latest reported figures
- VCYT's LTM Jun 2026 revenue of $561.9M is the 4th highest of the 10 companies compared; the peer median is $397.41M.
- Its year-over-year change of +17.3% is the 5th highest of 10, against a peer median of +11.2%.
- Over three fiscal years its annual growth of +20.4% compares with a peer median of +29.8%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $1.28B | +41.7% | +29.8% | |
| LTM Mar 2026 | $829M | -0.3% | +6.7% | |
| LTM Jun 2026 | $766.3M | +11.2% | +12.6% | |
| LTM Jun 2026 | $561.9M | +17.3% | +20.4% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $454.43M | +25.4% | +22.1% |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $397.41M | +90.1% | — |
| LTM Mar 2026 | $339.92M | -2.1% | +35.9% | |
| LTM Mar 2026 | $96.1M | +29.1% | +32.3% | |
| LTM Mar 2026 | $64.52M | -24.7% | — | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $1.95M | -49.3% | +61.8% |
| Peer median (excluding VCYT) | $397.41M | +11.2% | +29.8% | |
Competitors are the stored peer set for VCYT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 219.51M | 296.54M | 361.05M | 445.76M | 517.15M |
| Cost of Revenue | 74.4M | 101.58M | 112.9M | 147.62M | 157.1M |
| Gross Profit | 145.11M | 194.95M | 248.15M | 298.15M | 360.05M |
| Gross Margin | 66.1% | 65.7% | 68.7% | 66.9% | 69.6% |
| Research & Development | 29.84M | 40.6M | 57.31M | 69.29M | 70.81M |
| Selling, General & Admin | 181.19M | 174.08M | 184.23M | 206.04M | 210.95M |
| Operating Expenses | 227.02M | 236.04M | 333.94M | 282M | 285.9M |
| Depreciation & Amortization | 19.59M | 25.93M | 27.19M | 23.46M | 21.42M |
| EBITDA | (61.82M) | (10.3M) | (49.41M) | 49.21M | 89.62M |
| EBITDA Margin | -28.2% | -3.5% | -13.7% | 11.0% | 17.3% |
| Operating Income | (81.9M) | (41.08M) | (85.8M) | 16.14M | 74.15M |
| Operating Margin | -37.3% | -13.9% | -23.8% | 3.6% | 14.3% |
| Interest Income | 135K | 1.97M | 7.34M | 11.15M | 0 |
| Interest Expense | 241K | 198K | 15K | 2K | 0 |
| Other Income / Expenses | 254K | 4.65M | 9.18M | 9.6M | (5.95M) |
| Income Before Tax | (81.65M) | (36.43M) | (76.61M) | 25.74M | 68.2M |
| Pre-Tax Margin | -37.2% | -12.3% | -21.2% | 5.8% | 13.2% |
| Income Tax Expense | (6.09M) | 133K | (2.21M) | 1.61M | 1.85M |
| Net Income | (75.56M) | (36.56M) | (74.4M) | 24.14M | 66.35M |
| Net Margin | -34.4% | -12.3% | -20.6% | 5.4% | 12.8% |
| EPS (Basic) | (1.11) | (0.51) | (1.02) | 0.32 | 0.84 |
| EPS (Diluted) | (1.11) | (0.51) | (1.02) | 0.31 | 0.82 |
| Weighted Avg Shares | 67.89M | 71.55M | 72.64M | 76.48M | 78.58M |
| Weighted Avg Shares (Diluted) | 67.89M | 71.55M | 72.64M | 78.16M | 80.57M |
Veracyte, Inc.
NASDAQ:VCYT
Intrinsic Alpha fair value
Locked
Current Price
$25.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.